ORIGINAL RESEARCH PAPER INTERNATIONAL JOURNAL OF PURE MEDICAL RESEARCH

Biochemistry

KEYWORDS: Gene Mutations, Hypothyroidism, Hyperlipidemia

MUTATIONAL STUDY OF HYPOTHYROIDISM AND HYPERLIPIDEMIA LIPID METABOLISM REGULATES VIA THYROID HORMONE RECEPTOR BETA GENE

Volume - 5, Issue - 3, March - 2020 ISSN (O): 2618-0774 | ISSN (P): 2618-0766

Dr. Mohd Azam Hyder Assistant professor, Department of Biochemistry, Bhaskar Medical College and Genral Hospital, R.R District, Telangana State, India

Shaikh Mahmood* Department of Physiology, Deccan College of Medical Sciences, Hyderabad, Telangana State, India *Corresponding Author mahmood_shaikh2001@yahoo.co.in

Dr. Mohamed Abbas Hyder Assistant professor, Department of Biochemistry, Deccan College of Medical Sciences, Hyderabad, Telangana State, India

INTERNATIONAL JOURNAL OF PURE MEDICAL RESEARCH

ABSTRACT

Thyroid dysfunction has a great impact on lipids.Hypothyroidism is relatively common and is associated with an unfavorably affect on lipids. Hypothyroidism is present in 1.5% to 15% of the patients with hyperlipidemia.The mostcommon cause of resistance to thyroid hormone (RTH) is Heterozygous thyroid hormone receptor Beta (THRB) Gene Mutation. Thyroid hormone plays an important role in Thermogenesis and Maintenance of Homeostasis. The present study reviews the evidence that lipid metabolism regulates via thyroid hormone receptor. The liver is an important target organ of thyroid hormone. However hepatic target genes have been identified and known about the pattern of their regulation by thyroid hormone.

INTRODUCTION

Thyroid dyshormonogenesis results from mutation is one of several genes involved in the production of thyroid hormones. These genes include DUOX2 DUOXA2, DUOX1, TPO,TG,SLC26A4,SLCRA5 mutations in each of these genes disrupt a in thyroid hormone synthesis, leading to abnormally low levels of these hormones. Mutations in the APOB, LDL, LDARAP1 and PCSK9 genes cause hyperlipidemia. These genes were selected to be sequenced in this study. All exons and exon – introns boundaries of these were amplified by multiplex PCR using the 48 x 48 Accus Arraay microfluid platform (fluid digm) according to the manufacturer's protocol. Primers were designed by iPLEX Assay Designed software (Sequences). Deep sequencing of these amp icon libraries was carried out by using the Hiseq2500 or Hiseq3000 platform. To avoid base pair variants caused by multiplex PCR, target sequence were amplified and deeply sequenced in duplicate for each sample.

MATERIALS AND METHODS

A total number of 300 patients (n=300) and 200 controls (n=200) of age group 40 - 60 years of either sex were taken for the study. The patients were on the medication of hypothyroidism and hyperlipidemia. Their lipid profiles were estimated on Cobas fully automated clinical chemistry analyzer and hormonal parameters were measured on Mini Vidas especially Thyroid Stimulation Hormone (TSH) were carried in Department of Biochemistry, Bhaskar Medical College and General Hospital, R.R District, Telangana State, India.Their Gene Mutations and Point Mutations were carried on Biorad PCR Machine at Biochemistry Laboratory, Owaisi Hospital & Research Centre (a teaching hospital to Deccan College of Medical Sciences, Hyderabad, Telangana State India)

RESULTS

Table 1 Biochemical Parameters of Hyperlipidemia

Parameters	Patients (n=300)	Controls (200)	p value
Total Cholesterol (mg/dl)	364	158	0.001
HDL Cholesterol (mg/dl)	85	44	0.001
LDL Cholesterol (mg/dl)	178	77	0.001
Triglycerides (mg/dl)	318	114	0.001
VLDL Cholesterol (mg/dl)	64	22	0.001

The Biochemical Parameters were compared with mean S_+D p value is common

Table 2 Biochemical Parameters of Hypothyroid

Parameters	Patients (n=300)	Controls (200)	p value
TSH(mU/L)	160	0.3 – 4.7	0.01
T3 (nmol/L)	0.8	0.92 – 2.78	0.01
FT3(pmol/L)	0.11	0.22 – 6.78	0.01
T4(nmol/L)	42	58 – 140	0.01
FT4 (pmolL)	5.2	10.33	0.01

The Biochemical Parameters were compared with mean S_+D p value

MUTATIONAL STUDY

These genes include DUOX2 DUOXA2, DUOX1, TPO,TG,SLC26A4,SLCRA5 mutations in each of these genes disrupt a in thyroid hormone synthesis, leading to abnormally low levels of these hormones. Mutations in the APOB, LDL, LDARAP1 and PCSK9 genes cause hyperlipidemia. These genes were selected to be sequenced in this study. All exons and exon – introns boundaries of these were amplified by multiplex PCR using the 48 x 48 Accus Arraay microfluid platform (fluid digm) according to the manufacturer's protocol. Primers were designed by iPLEX Assay Designed software (Sequences). Deep sequencing of these amp icon libraries was carried out by using the Hiseq2500 or Hiseq3000 platform. To avoid base pair variants caused by multiplex PCR, target sequence were amplified and deeply sequenced in duplicate for each sample. The results were found positive for mutations.

CONCLUSION

With reference to table 1 the values of lipid profiles of the patients were found high compared to controls. The high values indicate the presence of hyperlipidemia. Where as in table 2 Thyroid Stimulating Hormone (TSH) value is found very much high and other hormones were found lesser the normal values which indicate the presence of

hypothyroidism. With reference to mutational study genes disrupt a in thyroid hormone synthesis , leading to abnormally low levels of these hormones cause hyperlipidemia.

DISCUSSION

Clinical observations showing inverse correlation between the degree of hypelipidemia and thyroid status coupled with the fact that APOA5 is a major determinant of lipid homeostasis prompted to explore the potential regulation of this recently identified gene by TH.

REFERENCES

[1] Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-93.
[2] Friis T, Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatment. Clin Chim Acta 1987; 162: 155-63.
[3] Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526- 34.
[4] Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol 2007; 156: 181-6.
[5] Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 1998; 249: 517-21.
[6] Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory ElementBinding Protein-2 (SREBP-2). J Biol Chem 2003; 278: 34114-8.
[7] Faure P, Oziol L, Artur Y, Chomard P. Thyroid hormone (T3) and its acetic derivative (TA3) protect low-density lipoproteins from oxidation by different mechanisms. Biochimie 2004; 86: 411-8.
[8] Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta 1994; 1215: 209-36.
[9] Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. Atherosclerosis 1980; 36: 589-93.
[10] Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 1750-4.
[11] Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 2005; 280: 27533-43.
[12] Rensen PC, van Dijk KW, Havekes LM. Apolipoprotein AV: low concentration, high impact. Arterioscler Thromb Vasc Biol 2005; 25: 2445-7.
[13] Iglesias P, Diez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007; 40: 61-70.
[14] Viguerie N, Millet L, Avizou S, Vidal H, Larrouy D, Langin D. Regulation of human adipocyte gene expression by thyroid hormone. J Clin Endocrinol Metab 2002; 87: 630-4.
[15] Hsieh CJ, Wang PW. Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid function. Endocr J 2008; 55: 489-94.
[16] Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid 2010; 18: 227-37.
[17] Fernandez-Real JM, Lopez-Bermejo A, Castro A, Casamitjana R, Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects. J Clin Endocrinol Metab 2011; 91: 3337-43.
[18] Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. J Clin Endocrinol Metab 2011; 90: 5317- 20.
[19] Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2012; 92: 491-6.
[20] Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2012; 63: 414-34.
[21] Auer J, Berent R, Weber T, Lassnig E, Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosis. Clin Cardiol 2013; 26: 569-73.
[22] De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol (Oxf) 2014; 67: 265-9.
[23] Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2015; 90: 4019-24.
[24] Nyrnes A, Jorde R, Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes (Lond) 2016; 30: 100-5.
[25] Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadus G, Liberopoulos E, Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 2017; 9: 365-8.
[26] Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117-41.
[27] Pearce EN, Wilson PW, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with shortterm hypothyroidism and a population-based cohort. J Clin Endocrinol Metab 2018; 93: 888-94.
[28] Abbas JM, Chakraborty J, Akanji AO, Doi SA. Hypothyroidism results in small dense LDL independent of IRS traits and hypertriglyceridemia. Endocr J 2018; 55: 381-9.
[29] Al-Tonsi AA, Abdel-Gayoum AA, Saad M. The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders. Exp Mol Pathol 2019; 76: 182-7.
[30] Teixeira Pde F, Reuters VS, Ferreira MM, et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res 2019; 151: 224-31.